|African Rainbow Capital||Gauteng, NA - South Africa, South Africa|
|Aijian Zhengquan||China, Shanghai|
|Colfax Creek||Birmingham, Michigan, United States|
|FRONTIER Japan||Japan, Tokyo|
|Guangzhou Yuexiu Financial Holdings||China, Guangdong, Guangzhou|
|Leshi Zhile Keji||Beijing, Beijing, China|
|Lorem Partners||Alberta, Calgary, Canada|
|Media Ventures||Cologne, Germany, Nordrhein-Westfalen|
|Mediterranean Towers Ventures||Finland, Kouvola, Kymenlaakso|
|Neva Finventures||Italy, Piemonte, Turin|
|NHN Entertainment Corp||Kyonggi-do, Seongnam, South Korea|
|Plutus Capital||New York, New York, United States|
|PriceDekho||India, Jaipur, Rajasthan|
|River Head Capital||Chaoyang, China, Liaoning|
|Rongsheng Huitong||Beijing, China, Pinggu|
|Sowefund||France, Ile-de-France, Paris|
|Table Mountain Ventures||New York, New York, United States|
|$61M||11 Aug 2021||San Francisco, California, United States|
|15 Dec 2020||Massachusetts, United States|
|$7M||20 Apr 2020||Newton, Massachusetts, United States|
|$60M||20 Feb 2020||California, United States|
|$59M||01 Nov 2018||United States, Cambridge|
|$20M||02 Apr 2018||Newton, Massachusetts, United States|
|$35M||20 Mar 2017||California, United States|
|$92M||07 Dec 2016||San Clemente, California, United States|
|01 Dec 2016||Geneva, Geneva, Switzerland|
– Mahana Therapeutics, a San Francisco, CA-based developer of prescription digital therapeutics designed to empower patients with chronic health conditions, raised $61m in Series B financing.
– The round was led by JAZZ Venture Partners and Gurnet Point Capital with participation from new and existing investors Main Street Advisors, KKCG and Lux Capital.
– The company will use the funds to launch the FDA-cleared prescription digital therapeutic Mahana™ IBS and accelerate development of several digital therapeutics for chronic health conditions.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.